FocalTherics (NASDAQ:FOCL) Director Fran Schulz Purchases 10,000 Shares of Stock

Key Points

• Director Fran Schulz bought 10,000 FocalTherics shares at $4.75 each, investing $47,500 and increasing her direct ownership by 196.08% to 15,100 shares.
• FocalTherics reported quarterly revenue of $13.2 million but missed earnings expectations, posting a loss of $0.39 per share versus the $0.20 consensus estimate. Analysts project a full-year loss of $0.78 per share.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $7.75 compared with the stock’s $4.76 opening price; institutional investors own 62.74% of shares.

FocalTherics (NASDAQ:FOCL - Get Free Report) Director Fran Schulz acquired 10,000 shares of the stock in a transaction on Friday, August 14th. The stock was bought at an average price of $4.75 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director directly owned 15,100 shares of the company's stock, valued at $71,725. This trade represents a 196.08% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

FocalTherics Stock Performance

FOCL stock opened at $4.76 on Monday. FocalTherics has a fifty-two week low of $1.30 and a fifty-two week high of $6.40. The stock's 50 day moving average price is $5.39. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. The stock has a market cap of $178.40 million, a P/E ratio of -4.62 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL - Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. The firm had revenue of $13.20 million during the quarter. Sell-side analysts forecast that FocalTherics will post -0.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on FOCL. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of FocalTherics in a research note on Tuesday, June 2nd. Piper Sandler reissued a "neutral" rating and issued a $4.00 price target on shares of FocalTherics in a research report on Friday. Mizuho set a $15.00 price target on FocalTherics and gave the stock an "outperform" rating in a research note on Friday, July 17th. Finally, Wall Street Zen lowered FocalTherics from a "hold" rating to a "sell" rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $7.75.

Institutional Trading of FocalTherics

Institutional investors and hedge funds have recently modified their holdings of the business. SmartHarvest Portfolios LLC purchased a new position in shares of FocalTherics in the first quarter worth $38,000. Lido Advisors LLC purchased a new position in FocalTherics in the 1st quarter worth about $40,000. Kovack Advisors Inc. purchased a new position in FocalTherics in the 4th quarter worth about $53,000. Leonteq Securities AG bought a new position in FocalTherics during the 4th quarter valued at about $313,000. Finally, Flax Pond Capital LLC bought a new position in FocalTherics during the 4th quarter valued at about $2,623,000. Institutional investors own 62.74% of the company's stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source